PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Eukaryotic translation initiation factors and cancer.

Abstract Recent technological advancements have shown tremendous mechanistic accomplishments in our understanding of the mechanism of messenger RNA translation in eukaryotic cells. Eukaryotic messenger RNA translation is very complex process that includes four phases (initiation, elongation, termination, and ribosome recycling) and diverse mechanisms involving protein and non-protein molecules. Translation regulation is principally achieved during initiation step of translation, which is organized by multiple eukaryotic translation initiation factors. Eukaryotic translation initiation factor proteins help in stabilizing the formation of the functional ribosome around the start codon and provide regulatory mechanisms in translation initiation. Dysregulated messenger RNA translation is a common feature of tumorigenesis. Various oncogenic and tumor suppressive genes affect/are affected by the translation machinery, making the components of the translation apparatus promising therapeutic targets for the novel anticancer drug. This review provides details on the role of eukaryotic translation initiation factors in messenger RNA translation initiation, their contribution to onset and progression of tumor, and how dysregulated eukaryotic translation initiation factors can be used as a target to treat carcinogenesis.
PMID
Related Publications

The mechanism of eukaryotic translation initiation and principles of its regulation.

Interaction between 25S rRNA A loop and eukaryotic translation initiation factor 5B promotes subunit joining and ensures stringent AUG selection.

Translational tolerance of mitochondrial genes to metabolic energy stress involves TISU and eIF1-eIF4GI cooperation in start codon selection.

Dynamics of ribosome scanning and recycling revealed by translation complex profiling.

Eukaryotic translation initiation factors in cancer development and progression.

Authors

Mayor MeshTerms

Carcinogenesis

Protein Biosynthesis

Keywords

Translation

cancer

eukaryotic initiation factors

therapy

tumorigenesis

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28653885
OWN - NLM
STAT- MEDLINE
DA  - 20170627
DCOM- 20170711
LR  - 20170713
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - Eukaryotic translation initiation factors and cancer.
PG  - 1010428317709805
LID - 10.1177/1010428317709805 [doi]
AB  - Recent technological advancements have shown tremendous mechanistic
      accomplishments in our understanding of the mechanism of messenger RNA
      translation in eukaryotic cells. Eukaryotic messenger RNA translation is very
      complex process that includes four phases (initiation, elongation, termination,
      and ribosome recycling) and diverse mechanisms involving protein and non-protein 
      molecules. Translation regulation is principally achieved during initiation step 
      of translation, which is organized by multiple eukaryotic translation initiation 
      factors. Eukaryotic translation initiation factor proteins help in stabilizing
      the formation of the functional ribosome around the start codon and provide
      regulatory mechanisms in translation initiation. Dysregulated messenger RNA
      translation is a common feature of tumorigenesis. Various oncogenic and tumor
      suppressive genes affect/are affected by the translation machinery, making the
      components of the translation apparatus promising therapeutic targets for the
      novel anticancer drug. This review provides details on the role of eukaryotic
      translation initiation factors in messenger RNA translation initiation, their
      contribution to onset and progression of tumor, and how dysregulated eukaryotic
      translation initiation factors can be used as a target to treat carcinogenesis.
FAU - Ali, Muhammad Umar
AU  - Ali MU
AD  - 1 Clinical Research Center, The Second Affiliated Hospital, Zhejiang University
      School of Medicine, Hangzhou, China.
FAU - Ur Rahman, Muhammad Saif
AU  - Ur Rahman MS
AD  - 1 Clinical Research Center, The Second Affiliated Hospital, Zhejiang University
      School of Medicine, Hangzhou, China.
FAU - Jia, Zhenyu
AU  - Jia Z
AD  - 2 Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences,
      Hangzhou, China.
FAU - Jiang, Cao
AU  - Jiang C
AD  - 1 Clinical Research Center, The Second Affiliated Hospital, Zhejiang University
      School of Medicine, Hangzhou, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (Codon, Initiator)
RN  - 0 (Eukaryotic Initiation Factors)
SB  - IM
MH  - *Carcinogenesis
MH  - Codon, Initiator/genetics
MH  - Eukaryotic Initiation Factors/*genetics
MH  - Gene Expression Regulation
MH  - Humans
MH  - Neoplasms/drug therapy/*genetics/pathology
MH  - *Protein Biosynthesis
MH  - Ribosomes/genetics
OTO - NOTNLM
OT  - Translation
OT  - cancer
OT  - eukaryotic initiation factors
OT  - therapy
OT  - tumorigenesis
EDAT- 2017/06/28 06:00
MHDA- 2017/07/14 06:00
CRDT- 2017/06/28 06:00
AID - 10.1177/1010428317709805 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317709805. doi: 10.1177/1010428317709805.